

## 2007 RESULTS

At its meeting of March 12, 2008, the Board of Directors of BOIRON, chaired by Christian BOIRON, approved the company financial statements and the consolidated financial statements in respect of the 2007 fiscal year. It was decided to call an Ordinary Shareholders' Meeting for May 15, 2008, at the Grand Hôtel Mercure Château Perrache in Lyon.

### CHANGE IN CONSOLIDATED RESULTS

Consolidated data as of December 31 (thousands of euros)	2006	2007	Change 2007/2006
Sales	398,674	434,294	8.9%
Current operating income	26,599	43,737	64.4%
Restructuring costs <sup>(1)</sup>	(8,512)	-	-
Net income – Group share	10,245	27,130	164.8%
Cash flow	37,334	62,037	66.2%
Net investment	16,095	18,459	14.7%
Net cash position	34,083	50,297	47.6%

<sup>(1)</sup> Restructuring costs stemming from the merger with Dolisos.

- 2007 saw an improvement in current operating income, which represented 10.1% of sales.
- Marketing expenses and research and development expenditure were up sharply, in line with the Group's strategic decisions.
- The Board of Directors will recommend to the Ordinary Shareholders' Meeting the distribution of a dividend of 0.55 euro per share. The dividend will be paid out on June 5, 2008.
- For Year 2008, the Group expects a new increase in sales and profitability.

*"For every PHYSICIAN in the world to integrate homeopathic medicines into daily practice."*

*Next update:*

*April 22, 2008: Publication in the media of sales and quarterly information as of March 31, 2008.*

*Person responsible for financial information: Philippe MONTANT*

*Financial information contact person: Véronique BOUSCAYROL*

*Investor relations: +33 (0) 4.78.45.62.74 - E-mail: [actionnaires@boiron.fr](mailto:actionnaires@boiron.fr)*

*ISIN code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA*